The first real therapeutic success of immunotherapy in cancer was the use of antibodies targeted to cancer cells, which harnessed the immune response to help deliver their therapeutic effect, such as rituximab (anti‐CD20) based on Fc engagement (Mellor et al, 2013), or trastuzumab (anti‐HER2) (Carter et al, 1992) based on FcR (and possibly other mechanisms). The gene discussed is ERBB2; the disease is cancer.